Related Experiment Video

Updated: Aug 23, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

CCR1 antagonists for the treatment of autoimmune diseases

Ronald P Gladue1, Samuel H Zwillich, Alan T Clucas

  • 1Pfizer Global Research and Development, Department of Immunology, MS 8220-2410, Eastern Point Road, Groton, CT 06340, USA. ronald_p_gladue@Groton.Pfizer.com

Current Opinion in Investigational Drugs (London, England : 2000)
|June 19, 2004
PubMed

Insights

Chemokine receptor CCR1 plays a key role in autoimmune diseases. Research shows that blocking CCR1 with small molecule antagonists is a promising therapeutic strategy currently under clinical investigation.

Area of Science:

  • Immunology
  • Pharmacology
  • Molecular Biology

Background:

  • Chemokines are small proteins crucial for regulating leukocyte infiltration to inflammatory sites.
  • Their involvement in human diseases and animal models highlights their therapeutic potential.
  • Chemokines interact with G protein-coupled receptors, making them attractive drug targets.

Purpose of the Study:

  • To review the evidence linking the chemokine receptor CCR1 to autoimmune disease pathogenesis.
  • To discuss the development of low molecular-weight CCR1 antagonists.
  • To outline the current clinical evaluation status of CCR1-targeting agents.

Main Methods:

  • Literature review of studies on CCR1 in autoimmune diseases.
  • Analysis of research on the identification and characterization of CCR1 antagonists.
  • Summary of clinical trial data for CCR1-targeting therapies.

Main Results:

  • Evidence supports CCR1's role in the pathogenesis of various autoimmune conditions.
  • Several low molecular-weight CCR1 antagonists have been identified.
  • Agents targeting CCR1 are currently undergoing clinical evaluation for autoimmune diseases.

Conclusions:

  • CCR1 is a significant target for treating autoimmune diseases.
  • Development of CCR1 antagonists shows therapeutic promise.
  • Ongoing clinical trials will determine the efficacy and safety of these agents.

More Related Videos

Induction of Experimental Autoimmune Encephalomyelitis in Mice and Evaluation of the Disease-dependent Distribution of Immune Cells in Various Tissues08:47

Induction of Experimental Autoimmune Encephalomyelitis in Mice and Evaluation of the Disease-dependent Distribution of Immune Cells in Various Tissues

Published on: May 8, 2016

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.